Eli Lilly (LLY) shares rose 4% premarket on Thursday after the drugmaker reported better-than-expected third-quarter results and raised its full-year 2026 revenue outlook, driven by strong demand for Mounjaro and Zepbound.
CryptoAlerta — análise de criptomoedas e mercado em tempo real